Leukotriene B4 as a potential therapeutic target for the treatment of metabolic disorders
- 1Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil
- 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
In the last decade, the incidence of metabolic disorders has increased drastically worldwide and is becoming a global health threat. Studies have shown that the pathogenesis and co-morbidities of diseases such as diabetes, gout, and atherosclerosis involve chronic low-grade inflammation and metabolic changes (1). As this inflammation is triggered by endogenous substances, instead of pathogens, it is called “sterile inflammation”. Chronic low-grade inflammation can be triggered by the accumulation of metabolic products such as uric acid, glucose, cholesterol, and free circulating fatty acids. These substances can induce inflammation by two distinct mechanisms: (1) engagement of Toll-Like Receptors (TLR), such as TLR-2 (2), TLR-4 (3), and TLR-9 (4) and (2) activation of the intracellular receptor complex known as inflammasome that leads to caspase-1 activation, an enzyme that cleaves pro- interleukin (IL)-1β into its active form (5–7). IL-1β acts on its receptor IL1R1, a member of the TLR family whose activation is dependent on the presence of the adaptor molecule Myeloid Differentiation primary response gene 88 (MyD88). Although TLR-2 signaling is mediated mainly through the MyD88, TLR-4 activates MyD88-dependent and TIR-domain-containing adapter-inducing interferon β (TRIF)-dependent pathways. The MyD88-dependent pathway culminates in the activation of the Nuclear Factor kappa B (NFκB)/Activator Protein (AP) 1 and the TRIF-dependent pathway leads to delayed activation of NFκB associated with Interferon Regulatory Factor (IRF) (8). Thus, NFκB is a transcription factor of several genes involved in inflammation and also regulates its own transcription (9). In metabolic diseases with chronic low-grade inflammation, NFκB is continuously activated (10). Since NFκB can be activated through the adaptor molecule MyD88, modulation of its expression should have important consequences on the inflammatory response.
Leukotrienes are lipid mediators whose production is increased during inflammation. Activated phospholipase A2 releases arachidonic acid from membrane phospholipids. Liberated (soluble) arachidonic acid can be metabolized by 5-lipoxygenase (5-LO) to produce leukotrienes including LTB4 and cysteinyl leukotrienes, LTC4, LTD4, and LTE4. It is well documented that leukotrienes are mediators of inflammatory events such as edema and leukocyte infiltration and activation and that they have an essential role in acute and chronic inflammatory diseases. Leukotrienes were also shown to mediate resistance to infections by several microorganisms (11). In macrophages, leukotrienes were shown to potentiate phagocytosis and microbicidal activity by affecting the mechanisms involved in actin polymerization and activation of NADPH oxidase, respectively (12).
LTB4 binds to two distinct G protein-coupled receptors. The Leukotriene Receptor (BLT)1 is the high affinity receptor that induces inflammation, enhances cytokine production, phagocytosis, and mediates antimicrobial effector functions. Through BLT1, LTB4 was shown to enhance MyD88 expression and potentiate MyD88-dependent stimuli responses while no difference on MyD88-independent stimuli was found (13). BLT2 binds LTB4 with lower affinity and has been much less studied, currently no information is available on BLT2 in the context with metabolic syndrome. It was shown that LTB4 through both, BLT2 and BLT1 receptors enhances NFκB activation (14).
It can be concluded that LTB4, by increasing MyD88 expression, would potentiate a TLR/IL-1R dependent sterile inflammation. Considering that metabolic diseases involve sterile inflammation we propose that LTB4 plays a central role in the development of metabolic diseases and may be considered a target for the development of new therapies. Here, we will highlight recent findings on LTB4 involvement in Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and gout.
According to the World Health Organization, diabetes is a syndrome characterized by hyperglycemia with disturbances in protein, lipid, and carbohydrate metabolism due to a deficiency in insulin production (in T1D) or insulin resistance (in T2D). In T1D, both hyperglycemia and insulin deficiency can be responsible for the sterile inflammation (15, 16). We found that mice with T1D exhibited higher serum levels of IL-1β, TNF-α, and LTB4. Macrophages from type 1 diabetic mice, compared to those from non-diabetics, expressed higher levels of MyD88 mRNA and produced higher levels of pro-inflammatory cytokines and nitric oxide, in response to MyD88-dependent stimuli such as LPS and IL-1β. Inhibition of LT synthesis restored MyD88 expression and cytokines production to similar levels found in macrophages from non-diabetic mice (15). Another important finding in this work was that pharmacologic or genetic inhibition of LTB4/BLT1 protected mice from succumbing to sepsis and this correlated with decreased macrophage MyD88 expression and decreased systemic inflammatory responses in the septic mice. This was an interesting finding because increased susceptibility to sepsis is a characteristic of diabetic patients (17).
In T2D, obesity is one of the largest risk factors for the development of insulin resistance (18, 19). It has been proposed that in obese people and in murine models of obesity, chronic sterile inflammation is triggered by free fatty acids (FFA), which engage MyD88-dependent receptors to produce IL-6 (20) and TNF-α (21). FFA can also activate the inflammasome and induce IL-1β production (7). Macrophages that infiltrate adipose tissue seem to play an essential role in insulin resistance. In diet-induced obesity, adipose tissue macrophages express an activated M1 phenotype (22–24). These results suggest that pro-inflammatory cytokines produced by macrophages have a local effect on adipocytes and a systemic effect on liver and muscle cells impairing insulin signaling.
In obese mice, increased uptake of omega-3-polyunsaturated fatty acids (ω-3-PUFA) led to enhanced insulin sensitivity. This correlated with decreased production of 5-LO products and increased generation of anti-inflammatory lipid mediators such as resolvins and protectins in the adipose tissue (25). Resolvins and protectins are mediators derived from ω-3-PUFA and are associated with the resolution phase of inflammation (26). Resolvin E1 can bind to BLT1, acting as a partial agonist to attenuate LTB4-induced NFκB activation in polymorphonuclear leukocytes. The effect of resolvin E1 was comparable to that of the BLT1 antagonist, U-75302 (27). Together these results suggest a dominant role for LTB4 through BLT1 in insulin resistance.
Recently, it was demonstrated that knockdown of the Ltb4r1 gene (the gene that transcribes BLT1) or inhibition of LTB4 synthesis protected mice from diet-induced insulin resistance (10, 28, 29). In mice fed a high-fat diet, increased amounts of LTB4 can be found in the white adipose tissue, liver, and muscle (29, 30). In obese animals, LTB4 promotes NFκB p65 nuclear translocation and production of IL-6 and TNF-α in adipose tissue (10). Moreover, when NFκB activation is increased, LTB4 could enhance pro-IL-1β expression for subsequent cleavage to the mature form via inflammasome activation.
Another possibility is that in skeletal muscle cells, adipocytes, and hepatocytes, LTB4 by enhancing MyD88 expression and action would potentiate the IL-1R response, further impairing insulin signaling in insulin target organs. LTB4 was also shown to decrease insulin signaling in hepatocytes through BLT1 by activating the NFκB pathway and up-regulating inhibitors of insulin pathways such as Phosphatase and Tensin homolog (PTEN) and Protein-Tyrosine Phosphatase 1B (PTP1B) (31). Thus, LTB4 could promote insulin resistance by enhancing macrophage pro-inflammatory cytokine production, potentiating IL-1β action in insulin target organs and negatively affecting different components of insulin action. Therefore, LTB4 is an essential mediator in the development of insulin resistance in T2D.
Retinal capillary degeneration is a hallmark of diabetic retinopathy, and there is evidence that LTB4 is involved in this diabetes co-morbidity. This is supported by studies in animal models of diabetic retinopathy. 5-LO-deficient mice exhibited decreased leukocyte adherence to the vascular wall (the leukocyte subset was not assessed in this study), superoxide generation, NFκB expression and did not exhibit signs of capillary degeneration (32, 33). Both superoxide generation and NFκB expression can be induced by MyD88-dependent events (34). In humans, leukotriene precursor levels were increased in vitreous samples from patients with diabetic retinopathy compared with samples from non-diabetics (35). These results show that the 5-LO pathway is important for the development of diabetic retinopathy in humans.
In gout, joint deposition of monosodium urate (MU), a byproduct of purine degradation, is the disease etiological agent. MU is to activate macrophage NLRP3 leading to IL-1β and IL-18 secretion (caspase-1-dependent), IL-6, CXCL1 and CXCL2 production and inflammatory cell recruitment (36). It has been shown that LTB4 is produced by macrophages stimulated with MU and in the knee-joint of mice injected with MU crystals. Amaral et al. showed that pharmacologic and genetic inhibition of LTB4 production or BLT1 antagonism reduced MU-induced IL-1β and CXCL1 production and this correlated with neutrophil migration to the joint. Moreover, the injection of LTB4 into the joint was sufficient to induce IL-1β production and neutrophil recruitment, suggesting an essential role for this lipid mediator in the pathogenesis of gout (37). In patients, LTB4 in gouty effusion was found at a higher concentration that in synovial fluid from patients with rheumatoid arthritis or osteoarthritis (38).
In summary, involvement of LTB4 on sterile inflammation in metabolic diseases is supported by the finding that inhibition of LTs synthesis or BLT1 antagonism: (a) reduced IL-1β and TNF-α serum levels in T1D (15) and MCP-1, IL-6, and TNF-α serum levels in T2D (29); (b) reduced the sterile inflammation in adipose tissue in obese mice, more specifically the macrophage infiltration (28), pro-inflammatory cytokine production (10), and NFκB activation (10); reduced neutrophil migration and IL-1β production in a murine model of gout (37); prevented diet-induced insulin resistance and steatosis (28, 30), and reduced susceptibility to sepsis in T1D mice (15).
Evidence presented here led us to propose that LTB4 has a central role in metabolic dysfunctions. By increasing MyD88 expression, LTB4 enhances macrophage response to TLR/IL1 receptor agonists potentiating the sterile inflammation, a central event in metabolic disease progression. Furthermore, LTB4 can amplify tissue injury by increasing reactive oxygen and nitrogen species that are known to mediate β-cell destruction, impairing insulin production. Although further studies are required, inhibition of the LTB4/BLT1 axis is a promising therapeutic strategy for the treatment of metabolic disorders. There is a 5-LO inhibitor already approved to treat asthma, and BLT1 antagonists are under development. Reduction in LTB4 production or activity may reduce sterile inflammation and decrease disease severity.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and the National Institute of Health (HL-103777-01 and HL-124159-01).
2. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum (2005) 52(9):2936–46. doi:10.1002/art.21238
3. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) (2008) 16(6):1248–55. doi:10.1038/oby.2008.210
4. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 139(1):323–34e7. doi:10.1053/j.gastro.2010.03.052
6. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 464(7293):1357–61. doi:10.1038/nature08938
9. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci U S A (1993) 90(6):2532–6. doi:10.1073/pnas.90.6.2532
10. Horrillo R, González-Périz A, Martínez-Clemente M, López-Parra M, Ferré N, Titos E, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol (2010) 184(7):3978–87. doi:10.4049/jimmunol.0901355
12. Morato-Marques M, Campos MR, Kane S, Rangel AP, Lewis C, Ballinger MN, et al. Leukotrienes target F-actin/cofilin-1 to enhance alveolar macrophage anti-fungal activity. J Biol Chem (2011) 286(33):28902–13. doi:10.1074/jbc.M111.235309
13. Serezani CH, Lewis C, Jancar S, Peters-Golden M. Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of myD88 expression. J Clin Invest (2011) 121(2):671–82. doi:10.1172/JCI43302
14. Sánchez-Galán E, Gómez-Hernández A, Vidal C, Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res (2009) 81(1):216–25. doi:10.1093/cvr/cvn277
15. Filgueiras LR, Brandt SL, Wang S, Wang Z, Morris DL, Evans-Molina C, et al. Leukotriene B4-mediated sterile inflammation promotes susceptibility to sepsis in a mouse model of type 1 diabetes. Sci Signal (2015) 8(361):ra10. doi:10.1126/scisignal.2005568
16. Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, Chaudhuri A, et al. Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care (2010) 33(5):1103–8. doi:10.2337/dc09-2193
18. Steinberger J, Moorehead C, Katch V, Rocchini AP. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr (1995) 126(5 Pt 1):690–5. doi:10.1016/S0022-3476(95)70394-2
19. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr (2000) 136(5):664–72. doi:10.1067/mpd.2000.105141
20. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science (2008) 322(5907):1539–43. doi:10.1126/science.1160794
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796–808. doi:10.1172/JCI200319246
24. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest (2006) 116(1):115–24. doi:10.1172/JCI24335C1
25. González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán-Salvador E, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 23(6):1946–57. doi:10.1096/fj.08-125674
27. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 178(6):3912–7. doi:10.4049/jimmunol.178.6.3912
28. Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, et al. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol (2011) 187(4):1942–9. doi:10.4049/jimmunol.1100196
29. Mothe-Satney I, Filloux C, Amghar H, Pons C, Bourlier V, Galitzky J, et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes (2012) 61(9):2311–9. doi:10.2337/db11-1455
30. Li P, Oh da Y, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med (2015) 21(3):239–47. doi:10.1038/nm.3800
31. Pardo V, González-Rodríguez Á, Guijas C, Balsinde J, Valverde ÁM. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J Biol Chem (2015) 290(18):11663–77. doi:10.1074/jbc.M115.649483
32. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes (2008) 57(5):1387–93. doi:10.2337/db07-1217
33. Talahalli R, Zarini S, Tang J, Li G, Murphy R, Kern TS, et al. Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol (2013) 93(1):135–43. doi:10.1189/jlb.0112025
35. Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes (2010) 59(7):1780–8. doi:10.2337/db10-0110
37. Amaral FA, Costa VV, Tavares LD, Sachs D, Coelho FM, Fagundes CT, et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum (2012) 64(2):474–84. doi:10.1002/art.33355
Keywords: Leukotriene B4, Diabetes, metabolic disorders, sterile inflammation, insulin resistance
Citation: Filgueiras LR, Serezani CH and Jancar S (2015) Leukotriene B4 as a potential therapeutic target for the treatment of metabolic disorders. Front. Immunol. 6:515. doi: 10.3389/fimmu.2015.00515
Received: 31 July 2015; Accepted: 22 September 2015;
Published: 08 October 2015
Edited by:Charles Dudley Mills, BioMedical Consultants, USA
Reviewed by:Janos G. Filep, University of Montreal, Canada
Heather M. Wilson, University of Aberdeen, UK
Copyright: © 2015 Filgueiras, Serezani and Jancar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sonia Jancar, firstname.lastname@example.org